Drug Database
TU

tuberculosis vaccine

✓ Approved

SK Chemicals · 细胞治疗 · 细胞治疗

什么是 tuberculosis vaccine?

tuberculosis vaccine 是一种细胞治疗,由SK Chemicals研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intradermal Injection。

药物档案

公司SK Chemicals
药物类别细胞治疗, 疫苗
给药途径Injectable (Others), Intradermal Injection
状态Approved

相关研究文献

PubMedJournal of medical cases2026-11-17

Prolonged Cholestasis as an Initial Presentation of Miliary Tuberculosis in a Pediatric Patient.

Zambrano Perez Carolina C, Rusinque Del Busto Ma Juliana MJ, Caceres Montejo Juliana J, Lopez Panqueva Rocio Del Pilar RDP et al.

Miliary tuberculosis is a severe form of tuberculosis resulting from hematogenous dissemination of Mycobacterium tuberculosis and may cause respiratory failure and multiorgan involvement in infants. Hepatic involvement is uncommon and may present as prolonged cholestasis and granulomatous hepatitis, making the diagnosis particularly challenging. We report an infant with miliary tuberculosis presenting with infantile cholestasis and acute respiratory failure. A 2-month-old infant presented with persistent cholestasis developed at 6 weeks of age and acute respiratory failure requiring noninvasive mechanical ventilation. Initial evaluation, including intraoperative cholangiography, excluded biliary atresia, and an extensive infectious, metabolic, autoimmune, immunologic, and genetic evaluation did not identify an alternative cause. Chest computed tomography demonstrated bilateral ground-glass opacities and peripheral micronodules in a miliary pattern. Liver biopsy showed granulomatous hepatitis with focal central necrosis and multinucleated giant cells. The diagnosis of Mycobacterium tuberculosis was confirmed by sputum polymerase chain reaction and acid-fast bacilli culture. A four-drug anti-tuberculosis regimen led to complete clinical, radiological, and biochemical resolution, with full recovery by 4 months of age. Miliary tuberculosis should be considered in infants presenting with severe respiratory failure, prolonged neonatal cholestasis, and granulomatous hepatitis, particularly in endemic regions. Early recognition of miliary pulmonary patterns on imaging and prompt initiation of targeted anti-tuberculosis therapy is critical to improve outcomes and ensure a favorable prognosis.

PMID 43042431
阅读全文 →
PubMedBMC public health2026-11-17

Post-introduction evaluation of COVID-19 vaccine deployment in Ghana: lessons learnt to inform future new vaccine introductions and strengthen public health readiness, 2023.

Amponsa-Achiano Kwame K, Shen Angela K AK, Baiden Laryea Eunice E, Carlton Julie Garon JG et al.

On March 2nd, 2021, Ghana, the first country to receive vaccines from the COVAX facility, began its COVID-19 vaccination using a complex multi-phased approach, to reach target populations. We evaluated the vaccine deployment to document best practices challenges and lessons for future new vaccine introductions and public health emergency readiness. We conducted a mixed methods post-introduction evaluation, purposively sampling 36 facilities from 12 districts in six regions. Adapting the World Health Organization's COVID-19 Post-Introduction Evaluation tool, we conducted a cross-sectional survey using a structured questionnaire, reviewed programme records, observed practices, and interviewed purposively selected health workers, immunization managers and partners who supported vaccine deployment. We performed summary descriptive statistics on quantitative data, thematic analysis on qualitative data, and triangulated the results. As of March 2023, more than 70% of the target population (15 years and older) had received at least one dose, while more than 50% had completed the primary series. Vaccine deployment was built on the existing immunisation programme and functional coordinating bodies. Cold chain capacity was revamped with ultra-low-temperature freezers, while 33.3% of surveyed districts adjusted waste disposal systems to accommodate COVID-19 vaccine introduction. Door-to-door delivery and demand generation through varied risk communication and community engagement strategies improved vaccine access. Electronic data platforms were established, surge capacity improved, and healthcare and community workers were trained. Initial unpredictable vaccine supplies limited vaccination efforts. Changing vaccine information affected health workers' ability to engage communities with up-to-date guidance. While vaccine safety monitoring systems were in place, reporting knowledge varied among health workers, and 36% of surveyed facilities had ever documented and reported COVID-19 vaccine-related adverse events following immunisation. Challenges with electronic data systems limited timely access to and use of granular service-delivery data for decision-making. Ghana leveraged existing immunisation and emergency-response systems to make substantial progress in COVID-19 vaccine deployment. Coordination, cold chain expansion, flexible service delivery, demand generation and workforce mobilisation supported implementation. Irregular vaccine supply, data system challenges, variable adverse event reporting, waste management pressure and misinformation challenged deployment. These findings provide lessons for adult immunisation, life-course vaccination and future public health emergency readiness.

PMID 43040294
阅读全文 →
PubMedACI open2026-11-17

Enhancing Human Papillomavirus Vaccine Communication with Mobile Health: Usability Insights from Caregivers and Health Care Providers.

Reisher Elizabeth E, Anyanwu Evangel E, Figliomeni Jonathan J, Honcoop Adrien A et al.

Despite the effectiveness of the human papillomavirus (HPV) vaccine in preventing cancer, uptake remains suboptimal, especially among rural and underserved populations. Digital communication tools such as mobile health (mHealth) applications have the potential to improve access to accurate vaccine information and support shared decision-making. This study aimed to assess the usability, acceptability, and perceived usefulness of a newly developed mHealth app for HPV vaccine communication in comparison to the Centers for Disease Control and Prevention's (CDC) HPV vaccine Web site. Using a mixed-methods design and guided by the Health Belief Model and the mHealth Agile Development and Evaluation Lifecycle, caregivers, and health care providers were randomized to explore both the CDC Web site and the mHealth app in alternating order. Participants were asked to complete a session answering HPV vaccine questions with each tool and completed the mHealth App Usability Questionnaire, Propensity to Trust, and NASA Task Load Index (NASA-TLX) after each session. Qualitative questions were asked after each session to capture additional feedback on items such as navigation and readability. Transcripts were analyzed using inductive thematic analysis. Quantitative results showed no difference between the tools in terms of being easy to use, requiring similar amounts of effort, and trust in the tool. Qualitative themes revealed that participants appreciated the app's streamlined navigation, tailored content, and readability. In contrast, the CDC Web site was seen as credible but often difficult to navigate, especially when searching for nuanced or specific vaccine information. Tailored mHealth tools developed with user-centered design principles may better meet the informational and usability needs of caregivers and health care providers compared with existing web-based resources. These findings support further development and integration of mHealth tools into vaccine communication strategies to enhance HPV vaccine communication.

PMID 43042227
阅读全文 →
PubMedInfection and immunity2026-11-17

Co-administration of DTaP with COVID-19 mRNA vaccine in mice alters immune responses and induces increased protection from Bordetella pertussis challenge.

Rader Nathaniel N, Boehm Dylan T DT, Bitzer Graham J GJ, Chapman Joshua J et al.

During the COVID-19 pandemic, children received COVID-19 mRNA vaccines alongside other regularly scheduled immunizations, such as the acellular Bordetella pertussis vaccine DTaP. It is known that mRNA vaccines are pro-inflammatory in nature, leading to protective immunity against SARS-CoV-2 infection. The goal of this study was to investigate the potential adjuvanticity of co-administration of a COVID-19 mRNA vaccine alongside DTaP. Mice were immunized with DTaP alone or with a co-administration of DTaP plus COVID-19 mRNA vaccine. To understand the impact of co-administration, we evaluated protection against B. pertussis aerosol challenge in mice and potential correlates of protection, including cytokine responses to vaccination, antibody responses, and single-cell transcriptomic analysis of the draining lymph node. Three decreasing doses of each vaccine were used to simulate waning immunity. Overall, compared to mice immunized with DTaP, co-administration of DTaP + COVID-19 mRNA vaccines elicited higher pro-inflammatory cytokine responses, higher IgG2b antibody responses, and mice were afforded increased protection against aerosol challenge of B. pertussis. Single-cell transcriptomics studies on the lymph node of vaccinated mice at 1 day post-boost further characterized how co-administration of COVID-19 mRNA vaccine alongside DTaP vaccine shapes immunity. Single-cell transcriptomics revealed that co-administration of DTaP and COVID-19 mRNA vaccine generated populations of B and T cells with upregulated expression of interferon-stimulated genes, which were absent when vaccinating with DTaP alone. Altogether, these data suggest that administering DTaP alongside COVID-19 mRNA vaccine alters immune responses and provides increased protection from an aerosol challenge of B. pertussis compared to DTaP alone in mice.

PMID 43043313
阅读全文 →
PubMedFrontiers in veterinary science2026-11-17

Ginsenoside Rg1 as an adjuvant enhances immunity in chickens immunized with the H9N2 avian influenza inactivated vaccine.

Zhang Pengju P, Wang Hongtao H, Li Mengman M, Lyu Xuefeng X et al.

To investigate the potential use of Ginsenoside Rg1 as an adjuvant for the H9N2 avian influenza vaccine, the study examined Rg1's immunomodulatory effects on an inactivated H9N2 vaccine. A total of 150 one-day-old non-immunized Arbor Acres (AA) chickens were randomly assigned to three groups (n = 50 each): one receiving the H9N2 inactivated vaccine, another receiving Rg1 alongside the vaccine, and a control group treated with PBS. Each group underwent three immunization sessions spaced 2 weeks apart. Serum samples were taken to measure IgG antibody levels and hemagglutination inhibition (HI) titers. Lymphocyte proliferation was assessed using cell counting kits-8 and flow cytometry. The levels of serum cytokines, including Interferon-γ (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-4, and IL-6, were quantified via ELISA. Fourteen days post-final immunization, the chickens were challenged with the H9N2 strain, and viral titers in the lungs and kidneys were measured. Findings indicated that the group receiving Rg1 with the vaccine exhibited a notable increase in specific IgG and HI titers. Furthermore, this group showed enhanced T cell proliferation and elevated cytokine production, thereby bolstering cellular immunity. Importantly, the immune protection results revealed that the combination of Rg1 and the vaccine significantly improved the chickens' protection against viral strains, leading to a marked reduction in viral shedding. These findings imply that Rg1 may enhance the immune response and protective efficacy of the H9N2 inactivated vaccine, positioning it as a promising new adjuvant for H9N2 vaccination.

PMID 43041234
阅读全文 →
PubMedFuture microbiology2026-11-17

Integration of molecular diagnostics and genomics to interpret silent rpoB mutations in Mycobacterium tuberculosis in Paraná State, Brazil.

Shibata Flávia Kazumi FK, Mangini Cicchelero Laiz L, Santos Leticia Graziela Costa LGC, Freund Aline Andrade AA et al.

To describe clinical isolates of Mycobacterium tuberculosis harboring the silent Phe433Phe mutation in the rpoB gene in Paraná State, Brazil, and to evaluate its role in diagnostic discordance and molecular surveillance. This study analyzed M. tuberculosis isolates processed at the Central Public Health Laboratory of Paraná between 2021 and 2023 showing discordant rifampicin resistance results between a molecular diagnostics assays line probe assay (LPA; GenoType MTBDRplus v2.0) and a rapid molecular test (GeneXpert® MTB/RIF Ultra). Phenotypic drug susceptibility testing was performed using an automated mycobacterial growth indicator tube system (BACTEC™ MGIT™ 960). Whole-genome sequencing was used to confirm mutations and assess genomic clustering. Among 3,351 isolates analyzed by LPA, 80 were classified as rifampicin-resistant by LPA, of which 31 (38.7%) exhibited an inferred mutation in the rpoB wt3 region while remaining susceptible according to rapid molecular testing and phenotypic assays. Most cases were concentrated in the 17th Health Region (71.0%), including individuals deprived of liberty (25.8%). Whole-genome sequencing of 22 viable isolates confirmed the silent Phe433Phe mutation. Genomic analysis identified clustered isolates compatible with recent transmission, particularly within prison-related settings. The silent Phe433Phe mutation is a potential epidemiological marker and a source of diagnostic discordance. Integrating molecular and genomic approaches is essential for tuberculosis surveillance.

PMID 43041093
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tuberculosis vaccine